Form 4: United Therapeutics CEO Executes Pre-Planned Stock Sale

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the reporting person sold the 9,500 shares in multiple tranches at weighted average prices ranging from $565.75 to $572.22.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The trading plan remains in effect until the earlier of December 31, 2026, or the exercise of 1,734,410 total stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned divestment by an executive that does not reflect a change in company fundamentals.

Positives

• The sale was executed under a pre-arranged 10b5-1 plan, indicating the transactions were scheduled in advance rather than based on non-public information.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including 40,513 shares held directly and substantial holdings in various family trusts.

Negatives

• The transaction represents a divestment of equity by the company's top executive, which may be perceived as a reduction in direct skin-in-the-game.

Risks

• The ongoing 10b5-1 plan involves the potential sale of up to 1,734,410 shares, which could exert downward pressure on the stock price if market liquidity is insufficient.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the earlier of December 31, 2026, or the exhaustion of 1,734,410 options.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by high-profile biotech CEOs are standard practice for liquidity and diversification, and generally do not signal a lack of confidence in the company's long-term pipeline or commercial performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at large-cap biotech firms like Amgen or Gilead to avoid allegations of insider trading.
• The scale of the sale relative to the CEO's total holdings is consistent with typical executive wealth management strategies.

Related Party Transactions

• The filing discloses holdings in various family trusts where the reporting person or spouse serves as trustee or beneficiary.

Stakeholder Impact

• Shareholders should note the ongoing scheduled selling pressure as the CEO continues to exercise and sell options under the 10b5-1 plan.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Martine Rothblatt, 10b5-1, Stock Options, Biotech